Stelo Launch And Dispelling GLP-1s: Dexcom’s Sayer Speaks

Dexcom’s CEO, Kevin Sayer, ahead of this year’s Advanced Technologies & Treatments for Diabetes conference, shared an update on the company’s recent news, future strategy and where he feels the market is headed.

On 5 March, Dexcom announced the US Food and Drug Administration had granted clearance to its Stelo blood glucose monitor, the first of its kind that will be sold over the counter.

Now, American type II diabetes patients who are not on insulin therapy will be able to easily access top-spec CGM...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

17 Jul 2025

• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

16 Jul 2025

• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

14 Jul 2025

• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.